Sabitlenmiş Tweet
𝗧𝗼𝗱𝗮𝘆, 𝗦𝗰𝗿𝗶𝗯𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗼𝗳𝗳𝗶𝗰𝗶𝗮𝗹𝗹𝘆 𝗯𝗲𝗰𝗮𝗺𝗲 𝗮 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹-𝘀𝘁𝗮𝗴𝗲 𝗯𝗶𝗼𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝗰𝗼𝗺𝗽𝗮𝗻𝘆 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗺𝗲𝗻𝘁 𝗼𝗳 𝗦𝗧𝗫-𝟭𝟭𝟱𝟬, a novel 𝘪𝘯 𝘷𝘪𝘷𝘰 epigenetic CRISPR therapy designed to deliver ultra-durable lowering of “bad cholesterol,” from a single dose, all without permanently altering the genome.
This program is built on years of intentional and iterative engineering focused on improving the safety, specificity, potency, and durability of CRISPR medicines.
𝗕𝘂𝘁 𝘄𝗵𝗮𝘁 𝗲𝘅𝗰𝗶𝘁𝗲𝘀 𝗺𝗲 𝗺𝗼𝘀𝘁 𝗶𝘀 𝘄𝗵𝗮𝘁 𝘁𝗵𝗶𝘀 𝗰𝗼𝘂𝗹𝗱 𝗺𝗲𝗮𝗻 𝗳𝗼𝗿 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗹𝗶𝗸𝗲 𝗺𝘆𝘀𝗲𝗹𝗳.
As someone at high risk of ASCVD, like roughly one-third of adults in the U.S., I’ve spent a lot of time thinking about the burden patients carry. For a chronic disease like ASCVD, prevention is far from easy. Success depends on maintaining near-perfect adherence to pills or injections for decades. In the real world, that’s incredibly difficult and simply not practical for most people. The fact that ASCVD remains the leading cause of death globally, despite plenty of therapeutic choices, makes that painfully clear.
𝗧𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝘀𝗵𝗼𝘂𝗹𝗱 𝗮𝘀𝗽𝗶𝗿𝗲 𝘁𝗼 𝗺𝗼𝗿𝗲 𝘁𝗵𝗮𝗻 𝗰𝗵𝗮𝗶𝗻𝗶𝗻𝗴 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝘁𝗼 𝗹𝗶𝗳𝗲𝗹𝗼𝗻𝗴 𝗺𝗲𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀.
The vision behind STX-1150 is to provide year to decades of LDL-C lowering from a simple intervention, helping free patients from the constant burden of chronic treatment while more effectively reducing the risk of the world’s leading cause of death.
The future is about empowering patients to take greater control of our own health destiny and preventing disease rather than waiting to treat it after catastrophe occurs.
𝗜 𝗯𝗲𝗹𝗶𝗲𝘃𝗲 𝗮 𝗻𝗲𝘄 𝗲𝗿𝗮 𝗼𝗳 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗶𝘀 𝗼𝗻 𝘁𝗵𝗲 𝗵𝗼𝗿𝗶𝘇𝗼𝗻, 𝗼𝗻𝗲 𝘄𝗵𝗲𝗿𝗲 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗰𝗮𝗻 𝗱𝘂𝗿𝗮𝗯𝗹𝘆 𝗿𝗲𝘀𝗵𝗮𝗽𝗲 𝗹𝗼𝗻𝗴-𝘁𝗲𝗿𝗺 𝗵𝗲𝗮𝗹𝘁𝗵 𝗮𝗻𝗱 𝗮𝗹𝗹𝗼𝘄 𝘂𝘀 𝗮𝗹𝗹 𝘁𝗼 𝗹𝗶𝘃𝗲 𝗹𝗼𝗻𝗴𝗲𝗿, 𝗵𝗲𝗮𝗹𝘁𝗵𝗶𝗲𝗿 𝗹𝗶𝘃𝗲𝘀 𝘄𝗶𝘁𝗵 𝗴𝗿𝗲𝗮𝘁𝗲𝗿 𝗳𝗿𝗲𝗲𝗱𝗼𝗺.
Extremely proud of the entire Scribe team for advancing this vision. Excited for what comes next.
Scribe Therapeutics@scribetx
Announcing our first clinical trial. Scribe has secured regulatory clearance from Australia’s @TGAgovau to initiate a first-in-human clinical study of STX-1150 for the treatment of hypercholesterolemia, a major driver of atherosclerotic cardiovascular disease (ASCVD). Details🧵
English
